CytoReason, a developer of computational disease models for efficient drug discovery and development, has signed a commercial partnership with Helixrus, a Korean company focused on biological big data and multi-omics, the company announced Tuesday. The partnership will see Helixrus represent CytoReason's unique artificial intelligence (AI) platform and professional services in the Korean market.
Follow Israel Hayom on Facebook, Twitter, and Instagram
CytoReason's multidisciplinary team of 65 leading biologists, bioinformaticians and data engineers has developed a technology that enables pharma and biotech companies to speed up drug R&D and bring novel therapies to patients.
The alliance will focus on leveraging Helixrus' knowledge of the Korean pharmaceutical market and network of relationships in Asian markets to highlight CytoReason's capabilities in prioritizing new targets, finding biomarkers, profiling combinations, stratifying patients, and other use cases within the drug lifecycle.
"We're thrilled to enter the Korean market with such an important player in South Korea's pharmaceutical industry," said David Harel, CEO and בo-founder of CytoReason. "Through this collaboration and others in Asian markets, our goal is to establish our computational disease models and professional services as the gold standard for drug discovery, development and portfolio management."
"We are very excited to partner with CytoReason as they expand their footprint into Korea," said Nick Choe, CEO of Helixrus, Inc. "CytoReason offers a unique AI drug discovery platform that already benefits a number of pharmaceutical companies worldwide, and we look forward to working together to improve drug discovery and development in Korea, as well."
